Using the computer controlled process DirectedDiversity® (see U.S. Patent 5,463,564), scientists at 3-Dimensional Pharmaceuticals, Inc. have generated a combinatorial library of compounds directed at the active site of human α-thrombin. Approximately 400 compounds were synthesized and assayed by a conventional spectrophotometric kinetic assay in which succinyl-Ala-Ala-Pro-Arg-p-nitroanilide (SEQ ID NO: 1) (Bachem, King of Prussia, PA) served as substrate. Five of these compounds, which are characterized by Ki's that span almost four orders of magnitude in binding affinity, were used to test the range and limits of detection of the thermal shift assay. These five proprietary compounds are listed in Table 3, along with the K<sub>i</sub> for each respective compound, as measured by the kinetic assay (last column). K<sub>i</sub>'s for these compounds ranged from 7.7 nM for 3dp-4026 to 20.0  $\mu$ M for 3dp-3811.

Please substitute the current version of the paragraph starting on page 19, line 1, and ending on page 19, line 2, with the following paragraph:

Figure 27 is a schematic diagram of a method of screening biochemical conditions that optimize protein folding. This method employs denatured protein tagged with H-H-H-H-H (SEQ ID NO: 2) or R-R-R-R-R (SEQ ID NO: 3).

Please insert the sequence listing at the end of the application.